Barrington Research Reiterates Haemonetics Outperform, $73 PT

Barrington Research reiterated its Haemonetics HAE Outperform rating and $73 price target in a research report published today. In the report, Barrington Research states, "We continue to have confidence in the long-term competitive position of HAE within the blood products industry." Shares of Haemonetics closed today at $64.96, down 0.11% from Monday's market close.